“Independent” Drug Safety Office Is Goal Of Senate Vioxx Investigation

The idea of an "independent" drug safety office in FDA merits consideration, Office of New Drugs Acting Director Sandra Kweder, MD, said during the Senate Finance Committee hearing Nov. 18 on Merck's withdrawal of Vioxx

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet